Cargando…

Bone marrow activation in response to metabolic syndrome and early atherosclerosis

AIMS: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Devesa, Ana, Lobo-González, Manuel, Martínez-Milla, Juan, Oliva, Belén, García-Lunar, Inés, Mastrangelo, Annalaura, España, Samuel, Sanz, Javier, Mendiguren, José M, Bueno, Hector, Fuster, Jose J, Andrés, Vicente, Fernández-Ortiz, Antonio, Sancho, David, Fernández-Friera, Leticia, Sanchez-Gonzalez, Javier, Rossello, Xavier, Ibanez, Borja, Fuster, Valentin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113301/
https://www.ncbi.nlm.nih.gov/pubmed/35567559
http://dx.doi.org/10.1093/eurheartj/ehac102
_version_ 1784709559392141312
author Devesa, Ana
Lobo-González, Manuel
Martínez-Milla, Juan
Oliva, Belén
García-Lunar, Inés
Mastrangelo, Annalaura
España, Samuel
Sanz, Javier
Mendiguren, José M
Bueno, Hector
Fuster, Jose J
Andrés, Vicente
Fernández-Ortiz, Antonio
Sancho, David
Fernández-Friera, Leticia
Sanchez-Gonzalez, Javier
Rossello, Xavier
Ibanez, Borja
Fuster, Valentin
author_facet Devesa, Ana
Lobo-González, Manuel
Martínez-Milla, Juan
Oliva, Belén
García-Lunar, Inés
Mastrangelo, Annalaura
España, Samuel
Sanz, Javier
Mendiguren, José M
Bueno, Hector
Fuster, Jose J
Andrés, Vicente
Fernández-Ortiz, Antonio
Sancho, David
Fernández-Friera, Leticia
Sanchez-Gonzalez, Javier
Rossello, Xavier
Ibanez, Borja
Fuster, Valentin
author_sort Devesa, Ana
collection PubMed
description AIMS: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. METHODS AND RESULTS: Whole body vascular (18)F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ((18)F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8–53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM (18)F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3–L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by (18)F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis—characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts—and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity ((18)F-FDG uptake). The co-occurrence of BM activation and arterial (18)F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). CONCLUSION: In apparently healthy individuals, BM (18)F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development. [Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].
format Online
Article
Text
id pubmed-9113301
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91133012022-05-18 Bone marrow activation in response to metabolic syndrome and early atherosclerosis Devesa, Ana Lobo-González, Manuel Martínez-Milla, Juan Oliva, Belén García-Lunar, Inés Mastrangelo, Annalaura España, Samuel Sanz, Javier Mendiguren, José M Bueno, Hector Fuster, Jose J Andrés, Vicente Fernández-Ortiz, Antonio Sancho, David Fernández-Friera, Leticia Sanchez-Gonzalez, Javier Rossello, Xavier Ibanez, Borja Fuster, Valentin Eur Heart J Clinical Research AIMS: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. METHODS AND RESULTS: Whole body vascular (18)F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ((18)F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8–53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM (18)F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3–L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by (18)F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis—characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts—and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity ((18)F-FDG uptake). The co-occurrence of BM activation and arterial (18)F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). CONCLUSION: In apparently healthy individuals, BM (18)F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development. [Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318]. Oxford University Press 2022-03-11 /pmc/articles/PMC9113301/ /pubmed/35567559 http://dx.doi.org/10.1093/eurheartj/ehac102 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research
Devesa, Ana
Lobo-González, Manuel
Martínez-Milla, Juan
Oliva, Belén
García-Lunar, Inés
Mastrangelo, Annalaura
España, Samuel
Sanz, Javier
Mendiguren, José M
Bueno, Hector
Fuster, Jose J
Andrés, Vicente
Fernández-Ortiz, Antonio
Sancho, David
Fernández-Friera, Leticia
Sanchez-Gonzalez, Javier
Rossello, Xavier
Ibanez, Borja
Fuster, Valentin
Bone marrow activation in response to metabolic syndrome and early atherosclerosis
title Bone marrow activation in response to metabolic syndrome and early atherosclerosis
title_full Bone marrow activation in response to metabolic syndrome and early atherosclerosis
title_fullStr Bone marrow activation in response to metabolic syndrome and early atherosclerosis
title_full_unstemmed Bone marrow activation in response to metabolic syndrome and early atherosclerosis
title_short Bone marrow activation in response to metabolic syndrome and early atherosclerosis
title_sort bone marrow activation in response to metabolic syndrome and early atherosclerosis
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113301/
https://www.ncbi.nlm.nih.gov/pubmed/35567559
http://dx.doi.org/10.1093/eurheartj/ehac102
work_keys_str_mv AT devesaana bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT lobogonzalezmanuel bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT martinezmillajuan bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT olivabelen bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT garcialunarines bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT mastrangeloannalaura bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT espanasamuel bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT sanzjavier bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT mendigurenjosem bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT buenohector bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT fusterjosej bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT andresvicente bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT fernandezortizantonio bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT sanchodavid bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT fernandezfrieraleticia bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT sanchezgonzalezjavier bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT rosselloxavier bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT ibanezborja bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis
AT fustervalentin bonemarrowactivationinresponsetometabolicsyndromeandearlyatherosclerosis